Glucotrack earnings release, May 14, 2026

Glucotrack, Inc. (GCTK) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Glucotrack

Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Submitted

Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology

Company targeting U.S. clinical trial launch in second half of 2026

Peer-Reviewed

Studies published in The Journal of Diabetes Research and in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support advancement of Company’s implantable CBGM technology

Rutherford,

NJ, May 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2026.

“During the quarter, we made meaningful progress advancing our CBGM program while further strengthening our foundation as a company,” said

Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We successfully completed our presub process with FDA, culminating in the submission of our IDE to the FDA, an important milestone that brings us closer to initiating U.S. clinical studies.

We also published two key sets of preclinical and in-vitro data in peer-reviewed journals, further supporting the development of our technology, and strengthened our balance sheet by reducing debt and extending our financial runway.”

First

Quarter 2026 & Recent Highlights

Corporate

Highlights

Advanced

Product and Clinical Development

Anticipated

Milestones

Financial

Results for the Quarter ended March 31, 2026

Research and Development Expenses:

Research and development expenses were $2.1 million for first quarter of 2026 compared to $1.9 million for first quarter of 2025. The increase of $0.2 million was primarily due to timing in product and manufacturing development activities.

General and Administrative Expenses:

General and Administrative expenses were $2.1 million for the first quarter of 2026 compared to $1.6 million for first quarter of 2025. The increase of $0.5 million was primarily attributable to increased professional fees and personnel costs.

Other

(Income) Expense, Net:

Other expense was $0.1 million for the first quarter 2026, as compared to $3.3 million for the first quarter of 2025. The decrease in other expense is primarily attributed to the current year’s reduction in the change of derivative liabilities.

Net

Loss:

Net loss for the first quarter of 2026 was $4.3 million compared to a net loss of $6.8 million for the first quarter of 2025.

The decrease in net loss is primarily attributed to the non-cash change in derivative liabilities.

Cash

Position:

Cash and cash equivalents as of March 31, 2026, were $3.9 million, compared with $7.4 million in cash and cash equivalents as of December 31, 2025. The net decrease in cash and cash equivalents was attributable to $4.1 million of cash used in operating activities offset by net proceeds received from financing activities of $0.6 million.

Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will provide sufficient runway into early 3Q 2026, allowing for the initiation of its U.S. human clinical trial shortly thereafter.

The

Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

About

Glucotrack, Inc.

Glucotrack,

Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The

Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack’s

Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

Forward-Looking

Statements

Financial statements

Income Statement

Three-month period ended March 31, — (in thousands of US dollars except share data) (unaudited)

Three-month period ended March 31, – 2026Three-month period ended March 31, – 2025
Operating expenses:Research and development2,1321,871
Operating expenses:General and administrative2,0711,627
Operating expenses:Total operating expenses4,2033,498
Operating expenses:Loss from operations4,2033,498
Other (income) expense:Change in fair value of derivative liabilities-13,376
Other (income) expense:Other (income) expense, net132-4
Other (income) expense:Finance expenses (income), net-37
Other (income) expense:Total other (income) expense1313,335
Other (income) expense:Net Loss4,3346,833
Other comprehensive income:Foreign currency translation adjustment-3-36
Other comprehensive income:Comprehensive loss for the period4,3316,797
Other comprehensive income:Basic and diluted loss per share2.6540.14
Other comprehensive income:Weighted average number of Common Stock outstanding used in computing basic and diluted loss per share1,638,128169,345

Balance Sheet

(i n thousands of US dollars except share data)

In thousands of US dollars (except stock data) – March 31, 2026 – UnauditedIn thousands of US dollars (except stock data) – December 31, 2025
Current AssetsCash and cash equivalents3,9297,383
Current AssetsOther current assets285284
Current AssetsTotal current assets4,2147,667
Current AssetsOperating lease right-of-use asset, net2633
Current AssetsProperty and equipment, net116138
Current AssetsTOTAL ASSETS4,3567,838
Current LiabilitiesAccounts payable1,2991,317
Current LiabilitiesOperating lease liability, current2628
Current LiabilitiesPromissory notes3,3303,182
Current LiabilitiesOther current liabilities320246
Current LiabilitiesTotal current liabilities4,9754,773
Non-Current LiabilitiesDerivative financial liabilities1
Non-Current LiabilitiesOperating lease liability, non-current5
Non-Current LiabilitiesLoans from stockholders232231
Non-Current LiabilitiesTotal liabilities5,2075,010
Common Stock of $0.001 par value (“Common Stock”):250,000,000 shares authorized as of March 31, 2026 and as of December 31, 2025; 2,524,279 and 910,688 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively31
Common Stock of $0.001 par value (“Common Stock”):Additional paid-in capital155,274151,080
Common Stock of $0.001 par value (“Common Stock”):Receipts on account of shares3,544
Common Stock of $0.001 par value (“Common Stock”):Accumulated other comprehensive income4441
Common Stock of $0.001 par value (“Common Stock”):Accumulated deficit-156,172-151,838
Common Stock of $0.001 par value (“Common Stock”):Total stockholders’ equity (deficit)-8512,828
Common Stock of $0.001 par value (“Common Stock”):TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)4,3567,838
Full release

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us... (trusiness or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on

Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.

Contacts:

GLUCOTRACK

INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Glucotrack earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.